Financials
Financial year 2025
RiethPharma from Mortsel, company number BE0824514648, closed financial year 2025 with a result of € 9,947 after tax. For that financial year RiethPharma recorded a gross margin of € 16,627 and equity of € 68,481. Compared with financial year 2024, the result moved from € -6,024 to € 9,947. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 4, 2026.
€ 68,481
▲ 17% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 9,947
▲ still € 6,024 loss in 2024
Profit after tax over the fiscal year.
€ 2,576
▼ 47% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 49,931.
People and assets in 2025
0
▼ 0.4 vs 2024
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
€ 347
Loans from banks and other lenders, long and short.
€ 48,610
▲ 44% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 20,330 | € 32,904 | € 33,315 | € 16,627 | ▼ 50% |
| Profit after taxes | € -12,973 | € -6,171 | € -6,024 | € 9,947 | ▲ € 15,972 |
| Equity | € 70,729 | € 64,558 | € 58,534 | € 68,481 | ▲ 17% |
| Total debts | € 60,122 | € 73,047 | € 55,335 | € 70,452 | ▲ 27% |
| Cash | € 2,939 | € 2,946 | € 4,874 | € 2,576 | ▼ 47% |
| Retained profit | € 52,179 | € 46,008 | € 39,984 | € 49,931 | ▲ 25% |
| Bank debt | € 22,923 | € 14,725 | € 0 | € 347 | |
| Balance sheet total | € 130,851 | € 137,605 | € 113,869 | € 138,933 | ▲ 22% |
| Employees (FTE) | - | 0.4 | 0.4 | 0 | ▼ 0.4 |
Key figures of RiethPharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to RiethPharma?
What happened at RiethPharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 9,947. filed late Source: NBB ↗
- KW-Beheer BV became a director. NBB
- New establishment in Mortsel. KBO
- Start of the company according to the CBE. KBO
In short
From € 12,973 loss in 2022 to € 9,947 profit in 2025.
Best year ever: 2025, with € 9,947 profit.
A new publication or filing at RiethPharma? We notify you, reason included.
Follow RiethPharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of KW-BEHEER comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
RiethPharmaBehind RiethPharma is KW-Beheer BV. The shares are held by KW-BEHEER (100%).
Directors
According to the 2025 annual accounts
Director · represented by Wustenberghs Kristina
since 2021
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Sint-Hathebrandstraat 6
2640 Mortsel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0824.514.648
- VAT number
- BE 0824.514.648
- Registered office
- Sint-Hathebrandstraat 6, 2640 Mortsel
- Names & denominations
- RiethPharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 March 2010
- Peppol
- Active · Active since 27 Nov 2025
- Activities · NACE
Detailhandel in farmaceutische producten